Determining the minimal clinically important difference and responsiveness of the dermatology life quality index (DLQI): Further data

Dermatology

Volumn 230, Issue 1, 2015, Pages 27-33

  Basra, M K A ^a   Salek, M S ^b   Camilleri, L ^c   Sturkey, R ^c   Finlay, A Y ^d  

^a DERRIFORD HOSPITAL   (United Kingdom)

^b UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

^c CARDIFF UNIVERSITY   (United Kingdom)

^d CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

DLQI; MCID; Minimum clinically important difference; Responsiveness; Skin disease

Indexed keywords

ADOLESCENT; ADULT; ADVERSE DRUG REACTION; AGED; ALLERGIC REACTION; ARTICLE; ASSESSMENT OF HUMANS; BLISTER; BULLOUS PEMPHIGOID; CUTANEOUS PARAMETERS; DERMATITIS; DERMATOLOGY LIFE QUALITY INDEX; DISEASE SEVERITY; ECZEMA; EROSIVE PUSTULAR DERMATOSIS; ERYTHROKERATODERMIA VARIABILIS; FEMALE; GLOBAL RATING OF CHANGE QUESTIONNAIRE; HUMAN; LONGITUDINAL STUDY; LUPUS VULGARIS; MAJOR CLINICAL STUDY; MALE; MINIMAL CLINICALLY IMPORTANT DIFFERENCE; NEURODERMATITIS; PHOTODERMATOSIS; PRIORITY JOURNAL; PSORIASIS; PSYCHOSIS BARBAE; QUALITY OF LIFE; RASH; REACTIVE LYMPHOID INFILTRATE; ROSACEA; SEBORRHEIC DERMATITIS; SUPPURATIVE HIDRADENITIS; TINEA VERSICOLOR; DERMATOLOGY; MIDDLE AGED; QUESTIONNAIRE; SKIN DISEASE; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DERMATOLOGY; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRES; SKIN DISEASES; YOUNG ADULT;

EID: 84923006902     PISSN: 10188665     EISSN: 14219832     Source Type: Journal    
DOI: 10.1159/000365390     Document Type: Article

References (32)

1. Guyatt G, Walter S, Norman G: Measuring change over time: assessing the usefulness of evaluative instruments. J Chronic Dis 1987; 40:171-178.
2. Wright JG: The minimal important difference: who's to say what is important. J Clin Epidemiol 1996; 49:1221-1222.
3. Juniper EF, Guyatt GH, Willan A, Griffith LE: Determining a minimal important change in a disease-specific quality of life questionnaire. J Clin Epidemiol 1994; 47:81-87.
4. Jaeschke R, Singer J, Guyatt GH: Ascertaining the minimal clinically important difference. Control Clin Trials 1989; 10:407-415.
5. Crosby RD, Kolotkin RL, Williams GR: Defining clinically meaningful change in health-related quality of life. J Clin Epidemiol 2003; 56:395-407.
6. Finlay AY, Khan GK: Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19:210-216.
7. Basra MKA, Fenech R, Gatt RM, et al: The Dermatology Life Quality Index 1994-2007: a comprehensive review of validation data and clinical results. Br J Dermatol 2008; 159:997-1035.
8. Both H, Essink-Bot ML, Busschbach J, Nijsten T: Critical review of generic and dermatology-specific health-related quality of life instruments. J Invest Dermatol 2007; 127:2726-2739.
9. Le Cleach L, Chassany O, Levy A, et al: Poor reporting of quality of life outcomes in dermatology randomized controlled clinical trials. Dermatology 2008; 216:46-55.
10. Lewis V, Finlay AY: 10 years' experience of the Dermatology Life Quality Index (DLQI). J Invest Dermatol Symp Proc 2004; 9:169-180.
11. Mazzotti E, Barbaranelli C, Picardi A, Abeni D, Pasquini P: Psychometric properties of the Dermatology Life Quality Index (DLQI) in 900 Italian patients with psoriasis. Acta Derm Venereol 2005; 85:409-413.
12. Bronsard V, Paul C, Prey S, et al: What are the best outcome measures for assessing quality of life in plaque type psoriasis? A systematic review of the literature. J Eur Acad Dermatol Venereol 2010; 24(suppl 2):17-22.
13. Nijsten T, Meads DM, McKenna SP: Dimensionality of the Dermatology Life Quality Index (DLQI): a commentary. Acta Derm Vene-reol 2006; 86:284-285.
14. Nijsten T, Meads DM, de Korte J, et al: Cross-cultural inequivalence of dermatology-specific health-related quality of life instruments in psoriasis patients. J Invest Dermatol 2007; 127:2315-2322.
15. Twiss J, Meads DM, Preston EP, et al: Can we rely on the Dermatology Life Quality Index as a measure of the impact of psoriasis or atopic dermatitis? J Invest Dermatol 2012; 132:76-84.
16. Hongbo Y, Thomas CL, Harrison MA, Salek S, Finlay AY: Translating the science of quality of life into practice: what do Dermatology Life Quality Index scores mean? J Invest Der-matol 2005; 125:659-664.
17. Khilji FA, Gonzalez M, Finlay AY: Clinical meaning of change in Dermatology Life Quality Index scores. Br J Dermatol 2002; 147 (suppl 2):50.
18. Shikiar R, Harding G, Leahy M, Lennow RD: Minimal important difference (MID) of the Dermatology Life Quality Index (DLQI): results from patients with chronic idiopathic urticaria. Health Qual Life Outcomes 2005; 3: 36.
19. Shikiar R, Willian MK, Okun MM, et al: The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of phase II study. Health Qual Life Outcomes 2006; 4:71.
20. Kowalski J, Ravelo A, Weng E, Slaton T: Minimal important difference (MID) of the Dermatology Life Quality Index (DLQI) in patients with axillary and palmar hyperhidrosis. J Am Acad Dermatol 2007; 56:AB52(P546).
21. Melilli L, Shikiar R, Thompson C: Minimal clinically important difference in Dermatology Life Quality Index in moderate to severe plaque psoriasis patients treated with ada-limumab. J Am Acad Dermatol 2006; 54: AB221(P2894).
22. Loo WJ, Diba VC, Chawla M, Finlay AY: Dermatology Life Quality Index: influence of an illustrated version. Br J Dermatol 2003; 148: 279-284.
23. Cohen J: Statistical Power Analysis for the Behavioural Sciences, ed 2. Hillsdale, Erlbaum Associates, 1988, pp 8-14.
24. Norman GR, Stratford P, Regehr G: Methodological problems in the retrospective computation of responsiveness to change: The lessons of Cronbach. J Clin Epidemiol 1997; 50: 869-879.
25. Stratford PW, Binkley JM, Riddle DM, Guyatt GH: Sensitivity to change of the Roland-Morris Back Pain Questionnaire: part 1. Phys Ther 1998; 78:1186-1196.
26. Hagg O, Fritzell P, Oden A, Nordwall A; the Swedish Lumbar Spine Study Group: Simplifying outcome measurement. Evaluation of instruments for measuring outcome after fusion surgery for chronic low back pain. Spine 2002; 27:1213-1222.
27. Revicki DA, Cella D, Hayes RD, Sloan JA, Lenderking WR, Aaronson NK: Responsiveness and minimal important differences for patient reported outcomes. Health Qual Life Outcomes 2006; 4:70.
28. Smith CH, Anstey AV, Barker JNWN, et al: British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. Br J Dermatol 2009; 161:987-1019.
29. Jayaprakasam A, Darvay A, Osborne G, Mc-Gibbon D: Comparison of assessments of severity and quality of life in cutaneous disease. Clin Exp Dermatol 2002; 27:306-308.
30. Sampogna F, Sera F, Abeni D: Measures of clinical severity, quality of life and psychological distress in patients with psoriasis: a cluster analysis. J Invest Dermatol 2004; 122:602-607.
31. Beaton DE, Bombardier C, Katz JN, Write JG: A taxonomy for responsiveness. J Clin Epidemiol 2001; 54:1204-1217.
32. Food and Drug Administration: Guidance for Industry-Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labelling Claims. Silver Spring, FDA, 2006.